A Dose Escalation and Expansion Study of GIGA-564 in Participants With Locally Advanced or Metastatic Solid Tumor Malignancies

This study is testing a new experimental cancer drug called GIGA-564 in people with advanced or metastatic solid tumors. The drug works by helping the immune system recognize and attack cancer cells. This is a dose-finding study to determine the safest and most effective doses. **You may be eligible if...** - You are 18 or older - You have an advanced or metastatic solid tumor that no longer responds to standard treatments - Your cancer is measurable on imaging scans - You are in good general health (ECOG score 0 or 1) - Your life expectancy is more than 3 months - Your heart, liver, kidney, and blood counts meet minimum requirements **You may NOT be eligible if...** - You received other investigational treatments recently (within 4 weeks or 5 half-lives) - You have active autoimmune disease requiring treatment - You have untreated or unstable brain metastases - You are pregnant or breastfeeding - You have significant heart rhythm problems or recent heart attack - You have active, uncontrolled infection Talk to your doctor to see if this trial is right for you.